$BETR
Better Home & Finance Holding Co

2022 Q2 Form 10-Q Financial Statement

#000110465922091110 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.631M $1.091M $3.765M
YoY Change 116.79% 991.29%
Operating Profit -$2.631M -$1.091M
YoY Change 116.79% 1008.82%
Interest Expense $420.5K $23.26K $7.110K
YoY Change 13377.24%
% of Operating Profit
Other Income/Expense, Net $3.996M $2.078M $7.230M
YoY Change -209.83% -197.11%
Pretax Income $1.786M $1.010M $3.472M
YoY Change -136.83% -145.29%
Income Tax
% Of Pretax Income
Net Earnings $1.786M $1.010M $3.472M
YoY Change -136.83% -158.09% -17458.3%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $51.39K $29.07K $99.90K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.28K $36.47K $37.65K
YoY Change -85.54% -98.18%
Cash & Equivalents $35.28K $36.47K $37.65K
Short-Term Investments
Other Short-Term Assets $324.4K $418.6K $526.7K
YoY Change -56.34%
Inventory
Prepaid Expenses $324.4K $418.5K $526.7K
Receivables $503.0K
Other Receivables
Total Short-Term Assets $359.7K $943.7K $1.067M
YoY Change -63.56% -52.84% 21245.5%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill $18.67M
YoY Change
Intangibles
YoY Change
Long-Term Investments $278.5M $278.0M $278.0M
YoY Change 0.17% 0.02%
Other Assets
YoY Change
Total Long-Term Assets $278.5M $278.0M $278.0M
YoY Change 0.17% 0.02% 49754.91%
TOTAL ASSETS
Total Short-Term Assets $359.7K $943.7K $1.067M
Total Long-Term Assets $278.5M $278.0M $278.0M
Total Assets $278.8M $279.0M $279.1M
YoY Change -0.06% -0.36% 49501.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.737M $6.190M $5.622M
YoY Change 1773.49%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $2.312M $1.812M $1.412M
YoY Change 400.19% 806.15%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.05M $8.002M $7.035M
YoY Change 1048.14% 1083.64% 1161.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.449M $19.77M $21.85M
YoY Change -74.71% -21.87%
Total Long-Term Liabilities $7.449M $19.77M $21.85M
YoY Change -74.71% -21.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.05M $8.002M $7.035M
Total Long-Term Liabilities $7.449M $19.77M $21.85M
Total Liabilities $17.50M $27.77M $28.88M
YoY Change -42.31% 7.08% 5078.85%
SHAREHOLDERS EQUITY
Retained Earnings -$2.263M -$4.049M -$5.059M
YoY Change -70.47% 1193.61% 25193.82%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.32M $8.216M $7.206M
YoY Change
Total Liabilities & Shareholders Equity $278.8M $279.0M $279.1M
YoY Change -0.06% -0.36% 49501.57%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income $1.786M $1.010M $3.472M
YoY Change -136.83% -158.09% -17458.3%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$80.80K -$377.9K -$1.030M
YoY Change -95.97% 368.19% 5048.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$420.5K -$23.26K $0.00
YoY Change 14551.22% -99.99%
Cash From Investing Activities -$420.5K -$23.26K $0.00
YoY Change 14551.22% -99.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 500.1K 400.0K 950.0K
YoY Change 97.26% -99.86% 4650.0%
NET CHANGE
Cash From Operating Activities -80.80K -377.9K -1.030M
Cash From Investing Activities -420.5K -23.26K 0.000
Cash From Financing Activities 500.1K 400.0K 950.0K
Net Change In Cash -1.190K -1.179K -79.60K
YoY Change -99.93% -100.06%
FREE CASH FLOW
Cash From Operating Activities -$80.80K -$377.9K -$1.030M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001835856
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
aurcu Redemption Of Shares Calculated Based On Number Of Business Days Prior To Consummation Of Business Combination
RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination
P2D
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
AURORA ACQUISITION CORP .
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity File Number
EntityFileNumber
001-40143
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1628701
dei Entity Address Address Line1
EntityAddressAddressLine1
20 North Audley Street
dei Entity Address City Or Town
EntityAddressCityOrTown
London
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
W1K 6LX
dei Entity Address Country
EntityAddressCountry
GB
dei City Area Code
CityAreaCode
+44(0)
dei Local Phone Number
LocalPhoneNumber
20 3931 9785
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35275
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37645
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
502956
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
324375
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
526674
CY2022Q2 us-gaap Assets Current
AssetsCurrent
359650
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1067275
CY2022Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
278466148
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
278022397
CY2022Q2 us-gaap Assets
Assets
278825798
CY2021Q4 us-gaap Assets
Assets
279089672
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7736580
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5622429
CY2022Q2 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2312395
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1412295
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10048974
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7034724
CY2022Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
7449304
CY2021Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
13340717
CY2021Q4 aurcu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
8505100
CY2022Q2 us-gaap Liabilities
Liabilities
17498279
CY2021Q4 us-gaap Liabilities
Liabilities
28880541
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20586422
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12263980
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2262818
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5058764
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
18324649
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7206261
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278825798
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279089672
CY2022Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2630587
CY2021Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1213442
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3721876
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1311862
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2630587
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1213442
us-gaap Operating Income Loss
OperatingIncomeLoss
-3721876
us-gaap Operating Income Loss
OperatingIncomeLoss
-1311862
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
420489
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3123
us-gaap Investment Income Interest
InvestmentIncomeInterest
443751
us-gaap Investment Income Interest
InvestmentIncomeInterest
3123
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3813346
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4198067
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5891413
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6035035
CY2021Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
559839
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1056000
aurcu Offering Costs Derivative Warrant Liabilities
OfferingCostsDerivativeWarrantLiabilities
299523
CY2022Q2 aurcu Gain On Deferred Underwriting Fee
GainOnDeferredUnderwritingFee
182658
aurcu Gain On Deferred Underwriting Fee
GainOnDeferredUnderwritingFee
182658
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
1785906
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4848547
us-gaap Net Income Loss
NetIncomeLoss
2795946
us-gaap Net Income Loss
NetIncomeLoss
-6587297
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7206261
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1010040
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
8216301
CY2022Q2 aurcu Derecognition Of Deferred Underwriting Fee
DerecognitionOfDeferredUnderwritingFee
8322442
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
1785906
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
18324649
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5000
aurcu Units Issued During Period Shares New Issues
UnitsIssuedDuringPeriodSharesNewIssues
24300287
CY2021Q1 aurcu Units Issued During Period Value New Issues
UnitsIssuedDuringPeriodValueNewIssues
214438838
CY2021Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
6860057
CY2021Q1 aurcu Common Stock Subject To Possible Redemption Value
CommonStockSubjectToPossibleRedemptionValue
243002870
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-1056000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1738750
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
10506275
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4848547
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
5657728
us-gaap Profit Loss
ProfitLoss
2795946
us-gaap Profit Loss
ProfitLoss
-6587297
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5891413
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6035035
aurcu Offering Cost Allocated To Warrant Liability
OfferingCostAllocatedToWarrantLiability
299523
aurcu Fair Value Adjustment Of Over Allotment Option Liablity
FairValueAdjustmentOfOverAllotmentOptionLiablity
-1056000
aurcu Gain On Deferred Underwriting Fee
GainOnDeferredUnderwritingFee
182658
aurcu Interest Income On Securities
InterestIncomeOnSecurities
3123
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-202299
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
737923
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-502956
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2114151
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-36896
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-458719
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2086681
aurcu Payments For Investment Of Cash In Trust Account
PaymentsForInvestmentOfCashInTrustAccount
443751
aurcu Payments For Investment Of Cash In Trust Account
PaymentsForInvestmentOfCashInTrustAccount
278002870
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-443751
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-278002870
aurcu Net Proceeds From Initial Public Offering
NetProceedsFromInitialPublicOffering
238142813
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
35000000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
6860057
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
900100
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
330653
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
900100
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
280333523
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2370
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
243972
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37645
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35275
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
243972
aurcu Offering Costs Included In Accounts Payable Accrued Expenses
OfferingCostsIncludedInAccountsPayableAccruedExpenses
557663
aurcu Proceeds From Related Party For Offering Cost
ProceedsFromRelatedPartyForOfferingCost
105927
aurcu Initial Classification Of Common Stock Subject To Possible Redemption
InitialClassificationOfCommonStockSubjectToPossibleRedemption
243002870
aurcu Initial Fair Value Of Warrant Liabilities
InitialFairValueOfWarrantLiabilities
14916913
aurcu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
8322442
aurcu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
8505100
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Aurora Acquisition Corp. (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on October 7, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company is not limited to a particular industry or geographic region for purposes of completing a Business Combination. The Company is an early stage and emerging growth company, and as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of May 10, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Aurora Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Merger Sub”), and Better HoldCo, Inc., a Delaware corporation (“Better”). All activity for the period from October 7, 2020 (inception) through June 30, 2022 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below, and activities in connection with entering into the Merger Agreement. Since our Initial Public Offering, our only costs have been identifying a target for our initial Business Combination, negotiating the transaction with Better, and maintaining our Company and SEC reporting. We do not expect to generate any operating revenues until after completion of our initial Business Combination. We generate non-operating income in the form of interest income on cash and cash equivalents. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as expenses as we conduct due diligence on prospective Business Combination candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has selected December 31 as its fiscal year end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company’s Initial Public Offering was declared effective on March 3, 2021. On March 8, 2021, the Company consummated the Initial Public Offering of 22,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units sold, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $220,000,000 which is described in Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 3,500,000 private placement units (the “Novator Private Placement Units”) at a price of $10.00 per Novator Private Placement Unit in a private placement to the sponsor, directors, and executive officers of the Company, generating gross proceeds of $35,000,000 . In addition, the Company consummated the sale of 4,266,667 warrants (the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant in a private placement to Novator Capital Sponsor Ltd., or Novator, an affiliate of Novator Capital Ltd. (the “Sponsor”) and certain of the Company’s directors and executive officers, generating gross proceeds of $6,400,000, which is described in Note 4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Transaction costs amounted to $13,946,641 consisting of $4,860,057 of underwriting fees, $8,505,100 of deferred underwriting fees (see Note 6) and $581,484 of other offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following the closing of Aurora’s Initial Public Offering on March 8, 2021, an amount equal to $255,000,000 ($10.00 per unit) (see Note 6) from the net proceeds from Aurora’s Initial Public Offering and the sale of the Private Placement Warrants was placed in the trust account (the “Trust Account”). Additionally, the cash held in the Trust Account comprises of gross proceeds from the Initial Public Offering of $220,000,000, $23,002,870 from the proceeds of the Underwriters over-allotment, $35,000,000 from 3,500,000 units at a price $10.00 per unit and interest income of $23,262. As of June 30, 2022, funds in the Trust Account totaled $278,466,148, and will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 10, 2021, the underwriters partially exercised their over-allotment option, resulting in an additional 2,300,287 Units issued for an aggregate amount of $23,002,870 in gross proceeds ($22,542,813 of net proceeds). In connection with the underwriters’ partial exercise of their over-allotment option, the Company also consummated the sale of an additional 306,705 Private Placement Warrants at $1.50 per Private Placement Warrant, generating total proceeds of $460,057.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering, the sale of the Novator Private Placement Units, the sale of the Private Placement Warrants and the partial exercise of the underwriters’ over-allotment option, although substantially all of the net proceeds are intended to be applied generally toward completing a Business Combination and to pay the deferred portion of the underwriters’ discount associated with the Initial Public Offering and partial exercise of the underwriters’ over-allotment option. The Company must complete its initial Business Combination with one or more target businesses that together have a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. Upon the closing of the Initial Public Offering, the exercise of the over-allotment option and Novator Private Placement, management has agreed that $10.00 per Unit sold in the Initial Public Offering, and in connection with the sale of the Novator Private Placement Units, including proceeds of the sale of the Private Placement Warrants and Novator Private Placement Units will be held in a Trust Account and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares, with the exception of the founder shares and Novator private placement shares, upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The shareholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account (initially $10.00 per share), calculated as of <span style="-sec-ix-hidden:Hidden_ZQ5mwzyy0EK4M42Z069EGw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. The Class A ordinary shares will be recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">If the Company seeks shareholder approval in connection with a Business Combination, it will need to receive an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who vote at a general meeting of the Company (assuming a quorum is present). If a shareholder vote is not required under applicable law or stock exchange listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor and the Company’s officers and directors have agreed to vote their Founder Shares (as defined in Note 5), Novator Private Placement Shares and any Public Shares purchased in or after the Initial Public Offering in favor of approving a Business Combination and to waive their redemption rights with respect to any such shares in connection with a shareholder vote to approve a Business Combination. However, in no event will the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001. Additionally, each public shareholder may elect to redeem its Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares without the Company’s prior written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sponsor and the Company’s directors and officers have agreed (a) to waive their redemption rights with respect to any Founder Shares, Novator Private Placement Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i) to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other provision relating to shareholders’ rights or pre-initial business combination activity, unless the Company provides the public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company will have until 24 months from the closing of the Initial Public Offering (the “Combination Period”) to complete a Business Combination. In the event that the Company does not consummate a Business Combination within 24 months from the consummation of the IPO, we can seek an extension (with no limit to such extension) provided we have our shareholder approval. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than 10 business days thereafter, redeem 100% of the outstanding Public Shares and Novator Private Placement Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (less up to $100,000 of interest to pay dissolution expenses and net of taxes payable), divided by the number of then outstanding Public Shares and Novator Private Placement Shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board of directors, dissolve and liquidate, subject in each case to its obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sponsor and the Company’s directors and officers have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, any Public Shares acquired by the Sponsor or the Company’s directors and officers and Novator Private Placement Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares and Novator Private Placement Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a third party for services rendered or products sold to the Company, or by a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent public accountants), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a condition to the consummation of the Business Combination, the board of directors of the Company has unanimously approved a change of the Company's jurisdiction of incorporation by deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. In connection with the consummation of the Business Combination, the Company will change its name to “Better Home &amp; Finance Holding Company.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks and Uncertainties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management has evaluated the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Management’s Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2022, the Company had $35,275 in its operating bank account, and a working capital deficit of $9,689,325.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Prior to the completion of the Initial Public Offering, the Company lacked the liquidity it needed to sustain operations for a reasonable period of time, which is considered to be one year from the issuance date of the financial statement. The Company has since completed its Initial Public Offering at which time capital in excess of the funds deposited in the Trust Account and/or used to fund offering expenses was released to the Company for general working capital purposes. In addition to the excess of funds, the Company issued an unsecured promissory note (the “Note”) to the Sponsor (“Payee”) pursuant to which the Company could borrow up to an aggregate principal amount of $4,000,000. Should the Company’s operating costs, in relation to its proposed business combination, exceed the amounts still available and not currently drawn under the promissory note, the Sponsor shall increase the amount available under the promissory note to cover such costs, subject to an aggregate cap of $12,000,000. This amount would be reflective of estimated total costs of the Company through August 15, 2023 in relation to the business combination, in the event the business combination is unsuccessful. In the event that the Company does not consummate a Business Combination within 24 months from the consummation of the IPO, we can seek an extension (with no limit to such extension) provided we have our shareholder approval. The Note was non-interest bearing and payable by check or wire transfer of immediately available funds or as otherwise determined by the Company to such account as the Payee may from time to time designate by written notice in accordance with the provision of the Note. Accordingly, management has since re-evaluated the Company’s liquidity and financial condition and determined that sufficient capital exists to sustain operations through the earlier of a Business Combination or one year from the date of this filing.</p>
aurcu Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2021Q1 aurcu Transaction Costs
TransactionCosts
13946641
CY2021Q1 aurcu Sale Of Stock Underwriting Fees
SaleOfStockUnderwritingFees
4860057
CY2021Q1 aurcu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
8505100
CY2021Q1 aurcu Sale Of Stock Other Offering Costs
SaleOfStockOtherOfferingCosts
581484
CY2021Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
23262
aurcu Condition For Future Business Combination Use Of Proceeds Percentage
ConditionForFutureBusinessCombinationUseOfProceedsPercentage
80
aurcu Condition For Future Business Combination Threshold Percentage Ownership
ConditionForFutureBusinessCombinationThresholdPercentageOwnership
50
aurcu Redemption Limit Percentage Without Prior Consent
RedemptionLimitPercentageWithoutPriorConsent
20
aurcu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
aurcu Redemption Period Upon Closure
RedemptionPeriodUponClosure
P10D
aurcu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
aurcu Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
100000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35275
CY2022Q2 aurcu Working Capital Deficit
WorkingCapitalDeficit
9689325
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, a significant accounting estimate included in these financial statements is the valuation of the warrant liability. Such estimates may be subject to change as more current information becomes available.</p>
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q2 aurcu Deferred Underwriting Fee Waived
DeferredUnderwritingFeeWaived
8500000
aurcu Gain On Deferred Underwriting Fee
GainOnDeferredUnderwritingFee
182658
CY2022Q2 aurcu Gain On Deferred Underwriting Fee
GainOnDeferredUnderwritingFee
182658
CY2022Q2 aurcu Deferred Underwriting Fee Waived
DeferredUnderwritingFeeWaived
8505100
CY2022Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11523444
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of credit risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Coverage of $250,000 and up to £85,000 by the Financial Services Compensation Scheme per financial institution in the United Kingdom. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2021Q4 aurcu Sponsor Agreement Forfeiture By Sponsor Upon Closing Of Private Warrants
SponsorAgreementForfeitureBySponsorUponClosingOfPrivateWarrants
0.50
CY2021Q4 aurcu Sponsor Agreement Sponsor Locked Up Shares Percentage
SponsorAgreementSponsorLockedUpSharesPercentage
0.20
CY2021Q1 aurcu Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
3
CY2021Q1 aurcu Units Sold In Gross
UnitsSoldInGross
23002870
CY2021Q1 aurcu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
22542813
CY2021Q1 aurcu Underwriting Fee In Percentage
UnderwritingFeeInPercentage
2
CY2022Q2 aurcu Deferred Fee Per Unit
DeferredFeePerUnit
0.35
CY2022Q2 aurcu Deferred Underwriting Fee Waived
DeferredUnderwritingFeeWaived
8505100
CY2022Q2 aurcu Percentage Of Holders Under Lockup Provision For Transfer Of Share Post Merger
PercentageOfHoldersUnderLockupProvisionForTransferOfSharePostMerger
0.01
aurcu Lockup Period For Transfer Of Shares Post Merger
LockupPeriodForTransferOfSharesPostMerger
P6M
aurcu Loss Contingency Demand Letters Received Number
LossContingencyDemandLettersReceivedNumber
2
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0

Files In Submission

Name View Source Status
0001104659-22-091110-index-headers.html Edgar Link pending
0001104659-22-091110-index.html Edgar Link pending
0001104659-22-091110.txt Edgar Link pending
0001104659-22-091110-xbrl.zip Edgar Link pending
aurcu-20220630.xsd Edgar Link pending
aurcu-20220630x10q.htm Edgar Link pending
aurcu-20220630xex31d1.htm Edgar Link pending
aurcu-20220630xex31d2.htm Edgar Link pending
aurcu-20220630xex32d1.htm Edgar Link pending
aurcu-20220630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
aurcu-20220630_def.xml Edgar Link unprocessable
aurcu-20220630_pre.xml Edgar Link unprocessable
aurcu-20220630_lab.xml Edgar Link unprocessable
aurcu-20220630x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aurcu-20220630_cal.xml Edgar Link unprocessable